Daily Medication Pearl: Ropeginterferon alfa-2b-njft (Besermi) for Polycythemia Vera

Article

Besermi is an interferon alfa-2b indicated for the treatment of adults with polycythemia vera.

Medication Pearl of the Day: Ropeginterferon alfa-2b-njft (Besermi)

Indication: Besermi is an interferon alfa-2b indicated for the treatment of adults with polycythemia vera (PV).

Insight:

  • Dosing: Recommended starting dose 100 mcg by subcutaneous injection every 2 weeks (50 mcg if receiving hydroxyurea).
  • Dosage form: Injection 500 mcg/mL solution in a single-dose prefilled syringe.
  • Adverse events (AEs): The most common adverse reactions reported in > 40% of patients were influenza-like illness, arthralgia, fatigue, pruritus, nasopharyngitis, and musculoskeletal pain
  • Mechanism of action: Interferon alfa belongs to the class of type I interferons, which exhibit their cellular effects in polycythemia vera in the bone marrow by binding to a transmembrane receptor termed interferon alfa receptor.
  • Manufacturer: PharmaEssentia

Sources:

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Mayo Clinic oncology pharmacy
Therapy session -- Image credit: pressmaster | stock.adobe.com
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Multiple myeloma awareness -- Image credit: Fauzi | stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.